Clearmind Medicine (CMND) News Today $1.29 +0.01 (+0.78%) Closing price 02/21/2025 04:00 PM EasternExtended Trading$1.28 -0.01 (-0.39%) As of 02/21/2025 07:46 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 Time Period Clearmind announces publication of patent for binge behavior treatmentFebruary 4, 2025 | markets.businessinsider.comClearmind Medicine Announces Publication of Patent for Binge Behavior Psychedelic Combination Treatment in MexicoFebruary 4, 2025 | globenewswire.comClearmind Medicine announces publication of European patent applicationJanuary 7, 2025 | markets.businessinsider.comClearmind Medicine Announces Shareholders Meeting ResultsJanuary 7, 2025 | globenewswire.comClearmind Medicine Announces the Publication of European Patent Application for Binge Behavior Psychedelic Combination TreatmentJanuary 6, 2025 | globenewswire.comClearmind Medicine Granted Patent for Binge Behavior Treatment by the Macau International Intellectual Property OfficeJanuary 2, 2025 | globenewswire.comClearmind Medicine to move forward with MEAI-based alcohol substituteDecember 27, 2024 | markets.businessinsider.comClearmind Medicine Inc.: Clearmind Medicine Receives IRB Approval for its FDA-Regulated Clinical TrialDecember 26, 2024 | finanznachrichten.deClearmind To Partner With Dr Glitter To Advance Development Of MEAI As Safe Alternative To AlcoholDecember 26, 2024 | markets.businessinsider.comClearmind Medicine Looks to Move Forward with its Novel Psychedelic MEAI- Based Alcohol SubstituteDecember 26, 2024 | globenewswire.comClearmind Medicine Shares Double on Trial ApprovalDecember 24, 2024 | marketwatch.comClearmind Medicine Receives IRB Approval for its FDA-Regulated Clinical TrialDecember 24, 2024 | globenewswire.comClearmind, Dr Glitter sign term sheet for development of alcohol substituteDecember 16, 2024 | markets.businessinsider.comClearmind Medicine and Dr Glitter Pty Ltd Sign Term Sheet for Mutual Development of Novel Psychedelic MEAI- Based Alcohol Substitute in ActivCrystal™ FormatDecember 16, 2024 | globenewswire.comAlcohol Use Disorder Market Set for Remarkable Growth During the Study Period (2020–2034) | DelveInsightDecember 12, 2024 | finance.yahoo.comClearmind Medicine Inc. (CWY0.SG)November 20, 2024 | ca.finance.yahoo.comClearmind Medicine Inc.: Clearmind Medicine Announces IRB Approval for FDA First-In-Human Clinical Trial of CMND-100 at Second Clinical SiteOctober 11, 2024 | finanznachrichten.deClearmind Medicine Announces IRB Approval for FDA First-In-Human Clinical Trial of CMND-100 at Second Clinical SiteOctober 10, 2024 | globenewswire.comClearmind Medicine patents new addiction treatmentSeptember 18, 2024 | uk.investing.comClearmind Medicine Announces the Notice of an International Patent Application for Pioneering Ibogaine Combination TherapySeptember 16, 2024 | globenewswire.comClearmind Medicine files patent for PTSD treatment compoundsSeptember 15, 2024 | uk.investing.comClearmind Medicine and Yissum File International Patent Application for Revolutionary Psychedelic Compounds for PTSD TreatmentSeptember 12, 2024 | globenewswire.comClearmind Medicine Announces Publication of International Patent Application for Innovative MDMA-Based Combination TreatmentSeptember 6, 2024 | globenewswire.comClearmind Medicine Announces Publication of its Patent Application for Innovative Ketamine-Based Combination TreatmentAugust 29, 2024 | globenewswire.comCould Psychedelics End Binge Drinking? A Breakthrough Patent Says YesAugust 24, 2024 | msn.comClearmind Medicine Granted U.S. Patent Approval for Binge Behavior TreatmentAugust 21, 2024 | globenewswire.comClearmind, Yissum Apply for International Patent for PsychedelicsAugust 16, 2024 | marketwatch.comClearmind Medicine and Yissum Expand Collaboration with International Patent Application for Generation 3.0 Psychedelic Compounds to Treat Mental DisordersAugust 16, 2024 | globenewswire.comClearmind Medicine: New Scientific Publication Shows MEAI's Potential as a Novel Weight Loss DrugAugust 6, 2024 | globenewswire.comClearmind Medicine Concludes the Successful Participation in the Psychedelic Medicine – Israel 2024 Conference: Presented Industry Leaders its Groundbreaking ResearchJuly 31, 2024 | globenewswire.comClearmind Medicine Signs an Agreement to Source Manufacturers and Distributors for its Alcohol Substitute Beverage ProductJuly 19, 2024 | globenewswire.comClearmind Medicine Obtains IND Approval from the FDA to Start the Phase I/IIa Clinical Trial with its Innovative Treatment for AlcoholismJuly 16, 2024 | globenewswire.comClearmind Medicine Announces Submission of US Patent Application for Treating Metabolic Syndrome and Weight-lossJuly 16, 2024 | globenewswire.comClearmind Medicine to Present Groundbreaking Research at Psychedelic Medicine – Israel 2024 ConferenceJuly 12, 2024 | globenewswire.comClearmind Medicine Granted Patent Approval in Hong Kong for its Binge Behaviors TreatmentJune 28, 2024 | globenewswire.comClearmind Medicine Secured Exclusive Global Rights to Innovative Psychedelic Compounds for PTSD TreatmentJune 20, 2024 | globenewswire.comClearmind Medicine Revolutionizes the $13 Billion NonAlcoholic Beverages Market with its Psychedelic-Based DrinkJune 11, 2024 | globenewswire.comClearmind Medicine Advances its Proprietary Psychedelic- Based Synthetic Alcohol Beverage ProductMay 10, 2024 | globenewswire.comWhy Clearmind Medicine Stock Is Moving HigherMay 7, 2024 | msn.comClearmind Medicine Inc.: Clearmind Medicine Secures Exclusive Global Rights to Breakthrough Psychedelic Compounds for PTSD TreatmentMay 7, 2024 | finanznachrichten.deClearmind Medicine Secures Exclusive Global Rights to Breakthrough Psychedelic Compounds for PTSD TreatmentMay 7, 2024 | globenewswire.comClearmind Medicine Inc.: Clearmind Applies to Cease Being a Reporting Issuer in CanadaMay 1, 2024 | finanznachrichten.deClearmind Applies to Cease Being a Reporting Issuer in CanadaApril 30, 2024 | globenewswire.comClearmind signs agreement for psychedelic compounds for mental disorders treatmentApril 17, 2024 | msn.comClearmind Medicine Announces Exclusive Licensing Agreement for Generation 3.0 Psychedelic Compounds for the Treatment of Mental DisordersApril 17, 2024 | finance.yahoo.comClearmind Medicine Announces Exclusive Licensing Agreement for Generation 3.0 Psychedelic Compounds for the Treatment of Mental DisordersApril 17, 2024 | globenewswire.comClearmind Medicine advances trial for alcohol use disorder treatmentApril 11, 2024 | uk.investing.comClearmind Medicine Inc.: Clearmind Medicine Files U.S. Patent Application for Psychedelic-Based Treatment for Eating DisordersApril 10, 2024 | finanznachrichten.deClearmind Medicine Files U.S. Patent Application for Psychedelic-Based Treatment for Eating DisordersApril 10, 2024 | globenewswire.comClearmind Medicine Inc.: Clearmind Medicine CEO Issues Letter to ShareholdersApril 9, 2024 | finanznachrichten.de Get Clearmind Medicine News Delivered to You Automatically Sign up to receive the latest news and ratings for CMND and its competitors with MarketBeat's FREE daily newsletter. Email Address CMND Media Mentions By Week CMND Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CMND News Sentiment▼0.000.60▲Average Medical News Sentiment CMND News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CMND Articles This Week▼01▲CMND Articles Average Week Get Clearmind Medicine News Delivered to You Automatically Sign up to receive the latest news and ratings for CMND and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies DRRX News Today LSB News Today CARA News Today CTXR News Today BCAB News Today NXTC News Today ENLV News Today MTEX News Today INAB News Today LSTA News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:CMND) was last updated on 2/22/2025 by MarketBeat.com Staff From Our PartnersWhat is this southern state hiding?The financial press had a field day this week after President Donald Trump and Department of Government Effici...Stansberry Research | SponsoredWhy Buffett and 100 members of Congress are Piling into this One InvestmentThis isn't just another investment. It might be the last retirement stock you'll ever need. But this win...Behind the Markets | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredBuy NVDA Now? After weeks of volatility, did President Trump just turn Nvidia (NVDA) into a raging BUY? The beloved chip...Chaikin Analytics | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredMarket down? Do this now.During Trump's first term, his tariffs sent gold prices soaring. Investors who acted early made a fortune. Now...Colonial Metals | SponsoredElon Takes Aim at Social SecurityElon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social...Altimetry | SponsoredNvidia’s Next Big Move Comes on Feb. 26Nvidia isn't the only company that benefits greatly from these earnings calls. That's because a handful of ...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Clearmind Medicine Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Clearmind Medicine With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
